Immuno-Oncology

The AJMC^® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

By Maggie L. Shaw

March 31st 2025

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

Travis Osterman, DO, MS, FAMIA, FASCO

Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

By Maggie L. Shaw

October 25th 2024

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

By Alana Hippensteele

September 15th 2024

Rates of ICI-related CVAEs and myocarditis were low, but the risk of mortality following CVAEs is high, underscoring the need for monitoring and management of these effects. | Image credit: Henadzy - stock.adobe.com

Early Recognition, Action Crucial for ICI-Induced Cardiovascular Adverse Effects

By Rose McNulty

August 30th 2024

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

By Mary Caffrey

August 24th 2024

More News

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

March 21st 2023

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).

Needle and vaccine

March 16th 2023

Study Shows Immune Response After COVID-19 Vaccine in Majority of Patients Treated With CAR T-Cell Therapy

The majority of CAR T-cell therapy recipients developed a humoral immune response to vaccination against SARS-CoV-2 in a recent study, with a more robust vaccine schedule linked to higher antibody titers.

March 15th 2023

What We’re Reading: Biomarker Testing in Kentucky; Opioid Guidelines Updated; EPA Limits in Drinking Water

Kentucky passes a bill to require insurers to cover biomarker tests for patients with cancer; CDC opioid guidelines updated in November may be too late for patients with chronic pain; the Environmental Protection Agency is proposing new limits to reduce dangerous human-manufactured chemicals in drinking water.

Kidneys

March 8th 2023

Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Sashi Naidu, MD, Carolina Blood and Cancer Care Associates

March 6th 2023

Dr Sashi Naidu: Partnering With Molecular Diagnostic Labs Facilitates Advanced Cancer Care

Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.

Skin cancer

March 1st 2023

Neoadjuvant Initiation of Pembrolizumab Improves Outcomes vs Adjuvant Therapy Alone in Advanced Melanoma

Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma.

With Broad Input, Clinical Pathways Making a Difference for End Users

February 23rd 2023

With Broad Input, Clinical Pathways Making a Difference for End Users

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

February 23rd 2023

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

Breast cancer

February 22nd 2023

Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC

Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).

Andrew Hertler, MD, FACP

February 20th 2023

New Century Health’s Andrew Hertler, MD, FACP: “You Have to Be Careful When You Look at Total Cost of Care”

Interview by Mary Caffrey

CAR T cells

February 18th 2023

Study Suggests Second-line Axi-Cel Is Cost-effective vs Standard Care in R/R DLBCL

Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Kidneys

February 16th 2023

After More Than 3 Years, Nivolumab With Cabozantinib Shows Sustained Response Over Sunitinib in RCC

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status.

Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years

February 9th 2023

Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years

Allison Inserro

Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.

Esophageal cancer

February 7th 2023

Zanidatamab, With Biparatopic Binding to HER2, Shows 84% OS in Phase 2 Study of Gastroesophageal Adenocarcinoma

The investigational therapy promises a new way to target HER2 while still using chemotherapy combinations.

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

February 4th 2023

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

Hayden E. Klein Rose McNulty

Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

February 3rd 2023

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.

'Persistent' Subset of Tumor Mutations May Predict Immunotherapy Response

January 26th 2023

"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response

A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.

Lymphoma cell

January 19th 2023

Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL

A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.

Dr Alonso V. Pacheco

January 17th 2023

There Is a Need to Identify Patients Most Likely to Benefit From Immunotherapies, Says Dr Alonso V. Pacheco

Laura Joszt, MA Justina Petrullo

New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

image of science

January 14th 2023

From Lymphomas to Myeloma, Bispecific Antibodies Make a Big Splash at ASH

At the 2022 annual meeting of the American Society of Hematology (ASH), customized cancer immunotherapy treatments now share the limelight with bispecific antibodies, which made news across disease states from large B-cell lymphoma to follicular lymphoma to multiple myeloma; as their name suggests, these treatments aim at 2 targets, increasing their potency against cancer.

Image of a brain

January 10th 2023

Immune Profiling Study Offers Potential New Patient-Stratification Tools in Glioblastoma

Jared Kaltwasser

The findings include the identification of a 12-gene signature that could be used to categorize patients as high or low risk.

image of chimeric antigen receptor (CAR) T-cell

January 7th 2023

How CAR T Therapies Stack Up Against Standard of Care for LBCL Across Lines of Treatment, Cost Perspectives

Christina Mattina

During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?

research shows Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL

January 7th 2023

ASH Abstracts Reveal Disparate CAR T-Cell Therapy Access and Outcomes in MM, DLBCL

Christina Mattina

Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies may differ by characteristics such as race, ethnicity, gender, and geographic location among patients with cancer.

the top 5 IVBM coverage of 2022

December 27th 2022

Top Institute for Value-Based Medicine® Content in 2022

Hayden E. Klein

Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.

Graphic with wording "top 5 Evidence-Based Oncology articles of 2022"

December 24th 2022

Top Articles From Evidence-Based Oncology™ in 2022

In 2022, the most-read articles published in Evidence-Based Oncology™ included the latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery.

Top 5 Most-Read Immuno-Oncology Articles of 2022

December 22nd 2022

Top 5 Most-Read Immuno-Oncology Articles of 2022

In 2022, the most-read news about immuno-oncology included an FDA approval for liver cancer, research findings on other potential therapies for liver cancer, a Q&A with a COTA Healthcare executive about how real-world evidence has changed, new possibilities for patients with solid tumors, and more.

December 21st 2022

Data Sharing From Cancer Drug Trials Falls Short of Promises, Study Authors Say

image of a health care provider and various icons indicating health and cost

December 13th 2022

ICYMI: Top Content From AMCP Annual Meeting

Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.

Image of a young male patient

December 8th 2022

Using Risk Factors to Guide CAR T Approach Before, After Infusion in B-ALL

Jaime Rosenberg

This paper follows the 10-year remission mark for the first child treated with CD19-targeted CAR (chimeric antigen receptor) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL), adding promise to the notion that the technology can provide long-term durable remissions in patients who are highly refractory to chemotherapy.

ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting

December 5th 2022

ICYMI: Top Highlights From the 2022 Patient-Centered Oncology Care® Meeting

<1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions